Cannabidiol - TALENT Biotech

Drug Profile

Cannabidiol - TALENT Biotech

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TALENT Biotech
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Serotonin 1 receptor agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Graft-versus-host disease

Most Recent Events

  • 13 Dec 2017 Kalytera Therapeutics initiates enrolment in a phase II trial in Graft versus host disease (Prevention) in Israel
  • 27 Nov 2017 Kalytera Therapeutics plans a multiple-dose, phase II trial for Graft-versus-host disease (Prevention) in patients following allogeneic haematopoietic cell transplantation in Israel, prior to year-end
  • 27 Nov 2017 Kalytera Therapeutics receives second patent allowance for cannabidiol in the prevention and treatment of graft versus host disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top